A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Evanthia GalanisS Keith AndersonErin L TwohyXiomara W CarreroJesse G DixonDavid Dinh TranSuriya A JeyapalanDaniel M AndersonTimothy J KaufmannRyan W FeathersCaterina GianniniJan C BucknerPanos Z AnastasiadisDavid SchiffPublished in: Cancer (2019)
Despite upregulation of Src signaling in patients with GBM, the combination of bevacizumab with dasatinib did not appear to significantly improve the outcomes of patients with recurrent GBM compared with bevacizumab alone.
Keyphrases
- placebo controlled
- double blind
- metastatic colorectal cancer
- phase iii
- phase ii
- open label
- clinical trial
- chronic myeloid leukemia
- cell proliferation
- study protocol
- tyrosine kinase
- randomized controlled trial
- phase ii study
- poor prognosis
- type diabetes
- metabolic syndrome
- tertiary care
- squamous cell carcinoma
- radiation therapy
- skeletal muscle
- locally advanced